AstraZeneca : AZN prévoit une très forte croissance 2021 mais fera encore mieux que ça !
>Résultats T4 : une guidance qui montre l’accélération d’AZN - AstraZeneca a parfaitement rempli son objectif 2020 en publiant hier une croissance de son BPA de 18% à changes constants. La société visait « mid to high teens at cer » soit 16% à 19%. 2021 devrait permettre d’accélérer encore la dynamique puisque la société vise un BPA entre 4,75 $ et 5,00 $ soit une croissance publiée de 18% à 24% (à peine aidé par un effet changes légèrement positif de 1-3%). Fait maje...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.